Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Dose ranging study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LIPO-102, Low | Experimental |
| |
| LIPO-102, Mid | Experimental |
| |
| LIPO-102, High | Experimental |
| |
| LIPO-102; Placebo | Experimental |
| |
| salmeterol xinafoate | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| salmeterol xinafoate, fluticasone propionate | Drug | LIPO-102 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety | physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events | 8 weeks treatment |
| Change in abdominal circumference | abdominal circumference | Baseline to 9 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in global clinician scale score | Baseline to 9 weeks | |
| Change in global patient scale score | Baseline to 9 weeks | |
| Change in Photonumeric scale score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Murray Maytom | Neothetics, Inc | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beverly Hills | California | United States | ||||
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068297 | Fluticasone-Salmeterol Drug Combination |
| D000068299 | Salmeterol Xinafoate |
| ID | Term |
|---|---|
| D000420 | Albuterol |
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo |
|
| salmeterol xinafoate | Drug | Salmeterol |
|
| Baseline to 9 weeks |
| Change in Patient Reported Outcome Score | Baseline to 9 weeks |
| San Diego |
| California |
| United States |
| New York | New York | United States |
| Raleigh | North Carolina | United States |
| Nashville | Tennessee | United States |
| Plano | Texas | United States |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Organic Chemicals |
| D000588 | Amines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000068298 | Fluticasone |
| D000730 | Androstadienes |
| D000736 | Androstenes |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |